Literature DB >> 9188549

In vivo sequence variability of human immunodeficiency virus type 1 envelope gp120: association of V2 extension with slow disease progression.

T Shioda1, S Oka, X Xin, H Liu, R Harukuni, A Kurotani, M Fukushima, M K Hasan, T Shiino, Y Takebe, A Iwamoto, Y Nagai.   

Abstract

According to the rate of depletion of CD4 cell counts, we grouped 12 cases of human immunodeficiency virus type 1 (HIV-1) infection as 6 rapid (21.0 to 33.8 cells per microl per month) and 6 slow (0.9 to 7.9 cells per microl per month) progressors and determined the individual viral quasispecies patterns by sequencing the genome region encoding the V1, V2, and V3 loops of envelope protein. Although the quasispecies structures varied widely from one individual to another, a strong correlation was observed between a low rate of disease progression and a high degree of genetic diversity of HIV-1. Furthermore, the V2 loop extension was observed specifically in individuals with slow or no disease progression, whereas basic amino acid substitutions in V3 characteristic of a viral phenotype shift from non-syncytium inducing to syncytium inducing were observed in patients with advanced stages of disease regardless of their rate of disease progression. Studies with recombinant viruses suggested that elongation of V2 potentially restricts the capacity of HIV-1 to replicate in macrophages. Thus, our results suggest the association of distinct sequence features of both V3 and V2 with particular patterns of disease progression. Elongation of the V2 loop may be a good predictor of slow disease progression, while basic substitutions of V3 without elongation of V2 are characteristic of rapid progression.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9188549      PMCID: PMC191717          DOI: 10.1128/JVI.71.7.4871-4881.1997

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  55 in total

1.  Antigenic diversity thresholds and the development of AIDS.

Authors:  M A Nowak; R M Anderson; A R McLean; T F Wolfs; J Goudsmit; R M May
Journal:  Science       Date:  1991-11-15       Impact factor: 47.728

2.  Relation of phenotype evolution of HIV-1 to envelope V2 configuration.

Authors:  M Groenink; R A Fouchier; S Broersen; C H Baker; M Koot; A B van't Wout; H G Huisman; F Miedema; M Tersmette; H Schuitemaker
Journal:  Science       Date:  1993-06-04       Impact factor: 47.728

3.  Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection.

Authors:  J Mulder; N McKinney; C Christopherson; J Sninsky; L Greenfield; S Kwok
Journal:  J Clin Microbiol       Date:  1994-02       Impact factor: 5.948

4.  Independent introduction of two major HIV-1 genotypes into distinct high-risk populations in Thailand.

Authors:  C Y Ou; Y Takebe; B G Weniger; C C Luo; M L Kalish; W Auwanit; S Yamazaki; H D Gayle; N L Young; G Schochetman
Journal:  Lancet       Date:  1993-05-08       Impact factor: 79.321

5.  Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure.

Authors:  W A Paxton; S R Martin; D Tse; T R O'Brien; J Skurnick; N L VanDevanter; N Padian; J F Braun; D P Kotler; S M Wolinsky; R A Koup
Journal:  Nat Med       Date:  1996-04       Impact factor: 53.440

6.  Genetic analysis of HIV-1 during rapid progression to AIDS in an apparently healthy man.

Authors:  S Oka; S Ida; T Shioda; Y Takebe; N Kobayashi; Y Shibuya; K Ohyama; K Momota; S Kimura; K Shimada
Journal:  AIDS Res Hum Retroviruses       Date:  1994-03       Impact factor: 2.205

7.  Characteristics of long-term asymptomatic infection with human immunodeficiency virus type 1 in men with normal and low CD4+ cell counts.

Authors:  I P Keet; A Krol; M R Klein; P Veugelers; J de Wit; M Roos; M Koot; J Goudsmit; F Miedema; R A Coutinho
Journal:  J Infect Dis       Date:  1994-06       Impact factor: 5.226

Review 8.  T-cell-mediated immunopathology versus direct cytolysis by virus: implications for HIV and AIDS.

Authors:  R M Zinkernagel; H Hengartner
Journal:  Immunol Today       Date:  1994-06

9.  Functional role of the V1/V2 region of human immunodeficiency virus type 1 envelope glycoprotein gp120 in infection of primary macrophages and soluble CD4 neutralization.

Authors:  A Koito; G Harrowe; J A Levy; C Cheng-Mayer
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103

10.  The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression.

Authors:  D D Richman; S A Bozzette
Journal:  J Infect Dis       Date:  1994-05       Impact factor: 5.226

View more
  35 in total

1.  Reevaluation of amino acid variability of the human immunodeficiency virus type 1 gp120 envelope glycoprotein and prediction of new discontinuous epitopes.

Authors:  Y Yamaguchi-Kabata; T Gojobori
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

2.  HIV-2 genetic evolution in patients with advanced disease is faster than that in matched HIV-1 patients.

Authors:  Helena Skar; Pedro Borrego; Timothy C Wallstrom; Mattias Mild; José Maria Marcelino; Helena Barroso; Nuno Taveira; Thomas Leitner; Jan Albert
Journal:  J Virol       Date:  2010-05-12       Impact factor: 5.103

3.  Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity.

Authors:  Manish Sagar; Xueling Wu; Sandra Lee; Julie Overbaugh
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

4.  Changes in the V3 region of gp120 contribute to unusually broad coreceptor usage of an HIV-1 isolate from a CCR5 Delta32 heterozygote.

Authors:  Paul R Gorry; Rebecca L Dunfee; Megan E Mefford; Kevin Kunstman; Tom Morgan; John P Moore; John R Mascola; Kristin Agopian; Geoffrey H Holm; Andrew Mehle; Joann Taylor; Michael Farzan; Hui Wang; Philip Ellery; Samantha J Willey; Paul R Clapham; Steven M Wolinsky; Suzanne M Crowe; Dana Gabuzda
Journal:  Virology       Date:  2007-01-18       Impact factor: 3.616

5.  Polymorphism in the interleukin-4 promoter affects acquisition of human immunodeficiency virus type 1 syncytium-inducing phenotype.

Authors:  E E Nakayama; Y Hoshino; X Xin; H Liu; M Goto; N Watanabe; H Taguchi; A Hitani; A Kawana-Tachikawa; M Fukushima; K Yamada; W Sugiura; S I Oka; A Ajisawa; H Sato; Y Takebe; T Nakamura; Y Nagai; A Iwamoto; T Shioda
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

6.  HIV variability in the liver and evidence of possible compartmentalization.

Authors:  Jason T Blackard; Gang Ma; Christina M Martin; Susan D Rouster; M Tarek Shata; Kenneth E Sherman
Journal:  AIDS Res Hum Retroviruses       Date:  2011-05-04       Impact factor: 2.205

7.  Variability in the human immunodeficiency virus type 1 gp120 Env protein linked to phenotype-associated changes in the V3 loop.

Authors:  Noah G Hoffman; Francoise Seillier-Moiseiwitsch; JaeHyung Ahn; Jason M Walker; Ronald Swanstrom
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

8.  Involvement of both the V2 and V3 regions of the CCR5-tropic human immunodeficiency virus type 1 envelope in reduced sensitivity to macrophage inflammatory protein 1alpha.

Authors:  Y Maeda; M Foda; S Matsushita; S Harada
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

9.  Selection of HIV variants with signature genotypic characteristics during heterosexual transmission.

Authors:  Manish Sagar; Oliver Laeyendecker; Sandra Lee; Jordyn Gamiel; Maria J Wawer; Ronald H Gray; David Serwadda; Nelson K Sewankambo; James C Shepherd; Jonathan Toma; Wei Huang; Thomas C Quinn
Journal:  J Infect Dis       Date:  2009-02-15       Impact factor: 5.226

10.  Genetic characterization of human immunodeficiency virus type 1 in elite controllers: lack of gross genetic defects or common amino acid changes.

Authors:  Toshiyuki Miura; Mark A Brockman; Chanson J Brumme; Zabrina L Brumme; Jonathan M Carlson; Florencia Pereyra; Alicja Trocha; Marylyn M Addo; Brian L Block; Alissa C Rothchild; Brett M Baker; Theresa Flynn; Arne Schneidewind; Bin Li; Yaoyu E Wang; David Heckerman; Todd M Allen; Bruce D Walker
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.